HTB | HIV i-Base

Global update: 90-day review ended early and cancelled 10,000 grants, millions of people will suffer

Featured Reduced dosing: a possible crisis response to ART stockouts and closed clinics 5 May 2025. Related: Special reports, Antiretrovirals, Treatment strategies, Treatment access.
Closed clinics and limited ART in Zimbabwe, PEPFAR and UNAIDS news 4 May 2025. Related: Early access, Treatment access.
The RIO study: Q&A about controlling HIV with bNAbs 21 April 2025. Related: Early access, Conference reports, Cure-related research, CROI 32 San Francisco 2025.
Lenacapavir EAP in the UK closed to new referrals: NHS England and Gilead fail to agree a price after more than two years 20 April 2025. Related: Early access, Antiretrovirals, Treatment access, Drug resistance, BHIVA news.
CROI 2025: Webcasts and other resources now open access 16 April 2025. Related: Conference reports, CROI 32 San Francisco 2025.
Continued reports from CROI 2025 13 April 2025. Related: Conference reports, Conference index, CROI 32 San Francisco 2025.
Viral failure on CAB/RPV-LA: overcoming drug resistance with second-generation INSTIs 13 April 2025. Related: Journal scan, Early access, Treatment strategies, Drug resistance.
CROI 2025: LAPTOP, EC rebounds after 32 years, two more HSCT cures 12 April 2025. Related: Conference reports, Antiretrovirals, Treatment strategies, CROI 32 San Francisco 2025.
Lancet Commission on gender justice and equality 9 April 2025. Related: Journal scan.
Changes to US policy jeopardises the lives of 500,000 children living with HIV by 2030 8 April 2025. Related: Treatment access.
CROI 2025: Rebecca Denison gives opening community talk on 40 years of HIV 7 April 2025. Related: Conference reports, Treatment advocacy, CROI 32 San Francisco 2025.
Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care 3 April 2025. Related: Journal scan, Early access, Special reports, Treatment access.
CROI 2025: BHIVA best of CROI feedback now online 1 April 2025. Related: Conference reports, On the web, CROI 32 San Francisco 2025.
Future meetings and webinars 2025 1 April 2025. Related: Future meetings.
People living with HIV need two shots of the mpox vaccine and likely a booster after two years 1 April 2025. Related: Journal scan, mpox.
CROI 2025: Two bNAbs enable viral suppression off-ART in African women in the FRESH cohort 1 April 2025. Related: Conference reports, Cure-related research, CROI 32 San Francisco 2025.
Cuts in aid: up to 10 million new HIV infections and almost 3 million related deaths by 2030 28 March 2025. Related: Journal scan, Treatment access.
Stopping ART safely if your clinic is closed or runs out of meds: a practical guide 25 March 2025. Related: Special reports, Treatment strategies.
Webinar on stopping ART if your clinic is closed: practical facts on safety and risk 24 March 2025. Related: Special reports, Treatment strategies, Treatment access, On the web.
CROI 2025: Introduction to this year’s conference 22 March 2025. Related: Conference reports, Conference index, CROI 32 San Francisco 2025.
CROI 2025: RIO study: Dual-bNABs keep viral load undetectable off-ART – plus a potential first case of vaccine-like HIV remission 21 March 2025. Related: Conference reports, Cure-related research, CROI 32 San Francisco 2025.
CROI 2025: Switching to daily fixed-dose doravirine/islatravir: two randomised phase 3 studies 20 March 2025. Related: Conference reports, Antiretrovirals, CROI 32 San Francisco 2025.
CROI 2025: Tecovirimat has no benefit against mpox in STOMP study 18 March 2025. Related: Conference reports, mpox, CROI 32 San Francisco 2025.
CROI 2025: Ensitrelvir significantly reduces risk of developing COVID-19 after household exposure 18 March 2025. Related: Conference reports, COVID-19, CROI 32 San Francisco 2025.
CROI 2025: N6LS: 4-monthly injectable bNAb with monthly injectable cabotegravir 18 March 2025. Related: Conference reports, Antiretrovirals, CROI 32 San Francisco 2025.
Summary of Australian guidelines for anal cancer screening in people living with HIV 18 March 2025. Related: Guidelines.
CROI 2025: Reducing Biktarvy from daily to only once, twice or three times a week 17 March 2025. Related: Conference reports, Antiretrovirals, Treatment strategies, CROI 32 San Francisco 2025.
CROI 2025: Potential for once-yearly lenacapavir injections 16 March 2025. Related: Conference reports, Antiretrovirals, PK and drug interactions, HIV prevention and transmission, CROI 32 San Francisco 2025.
CROI 2025: Delegates send open letter to protest US cuts 12 March 2025. Related: Conference reports, Treatment advocacy, CROI 32 San Francisco 2025.
CROI 2025: Stand Up For Science rally against Trump funding freeze 9 March 2025. Related: Conference reports, Treatment advocacy, CROI 32 San Francisco 2025.
HIV and vaccine denialist is proposed to head the US NIH: further alarm for global science 7 March 2025. Related: Treatment advocacy.
Global update: 90-day review ended early and cancelled 10,000 grants, millions of people will suffer 1 March 2025. Related: Special reports, Treatment access.
Responses to the UK government slashing international aid by 40% 26 February 2025. Related: Treatment access, Treatment advocacy.
Deleted words from official documents: LGBTQ, diversity, inclusion, transgender 26 February 2025. Related: Treatment access, Treatment advocacy.
Country update from Nigeria: current impact on HIV services 22 February 2025. Related: Special reports, Treatment access.
Semaglutide reduces alcohol and cigarette use in a randomised phase 2 study 12 February 2025. Related: Weight, diabetes, metabolic complications, Coinfections and complications.
News and resources linked to changes in US policy on international aid 7 February 2025. Related: Special reports.
Impact of US elections and executive orders on global health: waiver covers PEPFAR with restrictions 7 February 2025. Related: Special reports, Treatment access, Treatment advocacy.
IAS public letter: Why HIV could be poised for a monumental comeback 6 February 2025. Related: Treatment access, On the web.
Lenacapavir for PrEP submitted to EMA for EU and global use 4 February 2025. Related: Antiretrovirals, HIV prevention and transmission.
New mpox vaccination sites open in the UK 3 February 2025. Related: mpox.
Africa CDC special briefing on mpox and the impact of conflict 1 February 2025. Related: mpox.
EU license for injectable cabotegravir/rilpivirine injections expanded to include adolescents >12 years old 31 January 2025. Related: Antiretrovirals.
US issues temporary waiver to re-enable PEPFAR 29 January 2025. Related: Treatment access.
IAS statement: PEPFAR freeze threatens millions of lives 25 January 2025. Related: Treatment access.
Trump bans travel for US government scientists, presentations restricted, language bans, documents disappearing 23 January 2025. Related: Treatment access, Treatment advocacy, Research studies.
Almost 1 in 5 people in Switzerland disconnected from HIV care over 10 years: only half reconnected and with advanced infection 22 January 2025. Related: Special reports, Treatment strategies.
BHIVA pregnancy guidelines online for comment: deadline 25 January 20 January 2025. Related: Pregnancy, Guidelines.
Detailed results from PALM007 study: no clinical impact of tecovirimat against mpox clade 1 6 January 2025. Related: mpox, IDWeek 2024.
Tecovirimat news continues: Japan approval includes mpox indication 2 January 2025. Related: mpox.